Drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are ramping up US manufacturing and stockpiling inventory as the Trump administration considers a 100 per cent tariff on imported branded and patented medicines. Although enforcement is delayed for companies investing in US manufacturing …